Sindrome.del.Ovario.Poliquistico

166 Síndrome del Ovario Poliquístico
99
Veeck L, Edgard JW, Witmyer J, Sandow
BA, Acosta AA, García JE, et al. Maturation
and fertilization of morphologically
immature human oocytes in a program
of in vitro fertilization. Fertil Steril.
1983;39:594-602.
100
Tan SL, Child TJ, Gulekli B. In vitro maturation
and fertilization of oocytes from
unstimulated ovaries: predicting the
number of immature oocytes retrieved
by early follicular phase ultrasonography.
Am J Obstet Gynecol. 2002;186:
684-9.
101
Trounson A, Wood C, Kausche A. In
vitro maturation and the fertilization
and developmental competence
of oocytes recovered from untreated
polycystic ovarian patients. Fertil Steril.
1994;62:353-62.
102
Trounson A, Anderiesz C, Jones GM.
Maturation of human oocytes in vitro
and their developmental competence.
Reproduction. 2001;121:51-75.
103
Gulekli B, Child TJ, Chian RC, Tan SL.
Immature oocytes from unstimulated
polycystic ovaries: a new source of
oocytes for donation. Reprod Technol.
2001;10:295-7.
104
Lebovitz HE. Oral antidiabetic agents.
Med Clin North Am. 2004;88:847-63.
105
Lord JM, Flight IHK, Norman RJ.
Insulin-sensitising drugs (metformin,
troglitazone, rosiglitazone, pioglitazone,
D-chiro-inositol) for polycystic ovary
syndrome (Cochrane Review). In: The
Cochrane Library; 2004:4.
106
Lord JM, Flight IHK, Norman RJ. Metformin
in polycystic ovary syndrome:
systematic review and meta-analysis.
BMJ. 2003;327:951-6.
107
Kashyap S, Wells GA, Rosenwaks Z.
Insulin-sensitizing agents as primary
therapy for patients with polycystic
ovarian syndrome. Hum Reprod. 2004;
19:2474-83.
108
De Leo V, La Marca A, Ditto A, Morgante
G, Cianci A. Effects of metformin
on gonadotropin-induced ovulation in
women with polycystic ovary syndrome.
Fertil Steril. 1999;72:282-5.
109
Ehrmann DA, Barnes RB, Rosenfield
RL, Cavaghan MK, Imperial J. Prevalence
of impaired glucose tolerance and
diabetes in women with polycystic ovary
syndrome. Diabetes Care. 1999;22:
141-6.
110
Morin-Papunen LC, Koivunen RM,
Ruokonen A, Martikainen HK. Metformin
therapy improves the menstrual
pattern with minimal endocrine and
metabolic effects in women with polycystic
ovary syndrome. Fertil Steril.
1998;69:691-6.
111
Homburg R. Should patients with polycystic
ovarian syndrome be treated
with metformin? A note of cautious
optimism. Hum Reprod. 2002;17:853-6.
112
Seli E, Duleba AJ. Should patients with
polycystic ovarian syndrome be treated
with metformin? Hum Reprod. 2002;17:
2230-6.
113
Stadtmauer LA, Toma SK, Riehl RM, Talbert
LM. Metformin treatment of patients
with polycystic ovary syndrome undergoing
in vitro fertilization improves
outcomes and is associated with modulation
of the insulin-like growth factors.
Hum Reprod. 2001;17:3016-26.
114
Barbieri RL, Ryan KJ. Hyperandrogenism,
insulin resistance, and acanthosis
nigricans syndrome: a common endocrinopathy
with distinct pathophysiologic
features. Am J Obstet Gynecol.
1983;147:90-101.
115
Costello MF, Eden JA. A systematic
review of the reproductive system
effects of metformin in patients with
polycystic ovary syndrome. Fertil Steril.
2003;79:1-13.
116
Harborne L, Fleming R, Lyall H, Norman
J, Sattar N. Descriptive review of
the evidence for the use of metformin
in polycystic ovary syndrome. Lancet.
2003;361:1-8.
117
Fedorcsák P, Dale PO, Storeng R, Abyholm
T, Tanbo T. The effect of met-